Doug Mc Laughlin
About Doug Mc Laughlin
Doug McLaughlin is a Senior Scientist II at MOMA Therapeutics, where he leads Chemical Genomics efforts and manages protein panel annotation databases. He has extensive experience in the biotechnology field, having worked at several prominent companies including Rubius Therapeutics, Novartis, and Bristol-Myers Squibb.
Current Role at MOMA Therapeutics
Doug Mc Laughlin serves as a Senior Scientist II at MOMA Therapeutics, a position he has held since 2022. In this role, he leads the Chemical Genomics efforts, focusing on annotating binding pockets within specific protein classes. He manages database systems related to protein panel annotations and works with reversible, covalent, and photo-affinity ligands in various chemistry applications. His expertise includes utilizing advanced techniques such as ASMS, LC-MS ABPP, and intact mass for binding assays.
Previous Experience at Rubius Therapeutics
Prior to his current role, Doug worked at Rubius Therapeutics as a Senior Scientist and Head of Protein Sciences from 2019 to 2020. He was responsible for overseeing protein science initiatives and contributed to technology development both externally and in-house. His tenure at Rubius Therapeutics followed a previous position as a Scientist, where he worked from 2017 to 2019.
Professional Background in Biomedical Research
Doug has a diverse background in biomedical research, having worked at several prominent organizations. He was a Scientist I at Novartis Institutes for BioMedical Research (NIBR) from 2013 to 2015 and later advanced to Scientist II from 2015 to 2017. Before joining Novartis, he served as a Principal Research Associate at Bristol-Myers Squibb from 2007 to 2013. His early career included a role as a Marketing Associate at Vision BioSystems and a Laboratory Assistant at the Institute of Bioenergetics.
Education and Training in Biotechnology
Doug Mc Laughlin pursued his education at Penn State University, focusing on Separation and Purification Strategies for Biotechnology Products. He has been involved in the Biotechnology Training Program since 2008. Additionally, he studied Biology at the University of Massachusetts Boston, which provided a foundational understanding of biological sciences relevant to his career in biotechnology.